Pacific Shuanglin Bio pharmacy Co Ltd - Asset Resilience Ratio
Pacific Shuanglin Bio pharmacy Co Ltd (000403) has an Asset Resilience Ratio of 2.66% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Pacific Shuanglin Bio pharmacy Co Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1996–2025)
This chart shows how Pacific Shuanglin Bio pharmacy Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 000403 total asset value.
Liquid Assets Composition Over Time
This chart breaks down Pacific Shuanglin Bio pharmacy Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Pacific Shuanglin Bio pharmacy Co Ltd (000403) financial obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥259.80 Million | 2.66% |
| Total Liquid Assets | CN¥259.80 Million | 2.66% |
Asset Resilience Insights
- Limited Liquidity: Pacific Shuanglin Bio pharmacy Co Ltd maintains only 2.66% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Pacific Shuanglin Bio pharmacy Co Ltd Industry Peers by Asset Resilience Ratio
Compare Pacific Shuanglin Bio pharmacy Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Pacific Shuanglin Bio pharmacy Co Ltd (1996–2025)
The table below shows the annual Asset Resilience Ratio data for Pacific Shuanglin Bio pharmacy Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.69% | CN¥254.39 Million ≈ $37.22 Million |
CN¥9.47 Billion ≈ $1.39 Billion |
-0.37pp |
| 2024-12-31 | 3.06% | CN¥282.70 Million ≈ $41.37 Million |
CN¥9.25 Billion ≈ $1.35 Billion |
-1.85pp |
| 2023-12-31 | 4.91% | CN¥423.34 Million ≈ $61.95 Million |
CN¥8.63 Billion ≈ $1.26 Billion |
-0.39pp |
| 2022-12-31 | 5.29% | CN¥422.44 Million ≈ $61.82 Million |
CN¥7.98 Billion ≈ $1.17 Billion |
+1.99pp |
| 2021-12-31 | 3.30% | CN¥234.21 Million ≈ $34.27 Million |
CN¥7.09 Billion ≈ $1.04 Billion |
+2.93pp |
| 2017-12-31 | 0.38% | CN¥5.00 Million ≈ $731.66K |
CN¥1.32 Billion ≈ $193.24 Million |
+0.37pp |
| 2010-12-31 | 0.01% | CN¥50.10K ≈ $7.33K |
CN¥925.41 Million ≈ $135.42 Million |
+0.00pp |
| 2009-12-31 | 0.00% | CN¥47.45K ≈ $6.94K |
CN¥1.25 Billion ≈ $183.18 Million |
+0.00pp |
| 2008-12-31 | 0.00% | CN¥28.10K ≈ $4.11K |
CN¥1.21 Billion ≈ $177.76 Million |
-0.10pp |
| 2007-12-31 | 0.10% | CN¥1.69 Million ≈ $246.60K |
CN¥1.66 Billion ≈ $242.84 Million |
+0.07pp |
| 2006-12-31 | 0.03% | CN¥566.03K ≈ $82.83K |
CN¥1.71 Billion ≈ $249.56 Million |
0.00pp |
| 2005-12-31 | 0.03% | CN¥716.11K ≈ $104.79K |
CN¥2.08 Billion ≈ $304.74 Million |
-0.06pp |
| 2004-12-31 | 0.10% | CN¥2.05 Million ≈ $300.28K |
CN¥2.12 Billion ≈ $309.58 Million |
-0.43pp |
| 2003-12-31 | 0.53% | CN¥11.86 Million ≈ $1.74 Million |
CN¥2.24 Billion ≈ $327.93 Million |
+0.44pp |
| 2002-12-31 | 0.09% | CN¥1.34 Million ≈ $196.17K |
CN¥1.54 Billion ≈ $226.02 Million |
-4.33pp |
| 1996-12-31 | 4.42% | CN¥14.62 Million ≈ $2.14 Million |
CN¥330.76 Million ≈ $48.40 Million |
-- |
About Pacific Shuanglin Bio pharmacy Co Ltd
Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China and internationally. The company offers human serum albumin, human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen… Read more